Advances in the diagnostic and monitoring value of glycocalyx injury in inflammatory bowel disease

doi:10.11958/20231646

Abstract

Abstract:

Inflammatory bowel disease (IBD) is no cure at present, and only drugs and surgery can relieve symptoms, delay and reduce recurrence. Therefore, it is very important to monitor the disease activity. Glycocalyx, a polyglycoprotein complex covering luminal side of vascular endothelial cells, is supportive in maintaining the intestinal mucosal barrier, and inflammation leads to its structural damage. This review introduces currently available non-invasive biomarkers of clinical importance for IBD in laboratory testing, and analyzes the value of serum glycocalyx injury markers (syndecan-1, HS and HA) in the diagnosis or monitoring of IBD.

Key words: inflammatory bowel diseases, intestinal mucosa, syndecan-1, heparitin sulfate, hyaluronic acid, glycocalyx damage

CLC Number:

R446.1，R574.6

References 40

[1]	COLLABORATORS G I B D. The global,regional, and national burden of inflammatory bowel disease in 195 countries and territories,1990-2017:a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet Gastroenterol Hepatol, 2020, 5(1):17-30. doi:10.1016/S2468-1253(19)30333-4.
[2]	BRUSCOLI S, FEBO M, RICCARDI C, et al. Glucocorticoid therapy in inflammatory bowel disease:mechanisms and clinical practice[J]. Front Immunol, 2021, 12:691480. doi:10.3389/fimmu.2021.691480.
[3]	CORNISH J S, WIRTHGEN E, DABRITZ J. Biomarkers predictive of response to thiopurine therapy in inflammatory bowel disease[J]. Front Med(Lausanne), 2020, 7:8. doi:10.3389/fmed.2020.00008.
[4]	SCHOULTZ I, KEITA A V. The intestinal barrier and current techniques for the assessment of gut permeability[J]. Cells, 2020, 9(8):1909. doi:10.3390/cells9081909.
[5]	QU J, CHENG Y, WU W, et al. Glycocalyx impairment in vascular disease:focus on inflammation[J]. Front Cell Dev Biol, 2021, 9:730621. doi:10.3389/fcell.2021.730621.
[6]	XIE Z, BORSET M, SVEEN K, et al. Markers of endothelial glycocalyx dysfunction in Clarkson disease[J]. J Transl Med, 2022, 20(1):380. doi:10.1186/s12967-022-03587-1.
[7]	GRONDIN J A, KWON Y H, FAR P M, et al. Mucins in intestinal mucosal defense and inflammation:learning from clinical and experimental studies[J]. Front Immunol, 2020, 11:2054. doi:10.3389/fimmu.2020.02054.
[8]	ISKANDAR H N, CIORBA M A. Biomarkers in inflammatory bowel disease:current practices and recent advances[J]. Transl Res, 2012, 159(4):313-325. doi:10.1016/j.trsl.2012.01.001.
[9]	CHEN Y H, WANG L, FENG S Y, et al. The relationship between C-reactive protein/albumin ratio and disease activity in patients with inflammatory bowel disease[J]. Gastroenterol Res Pract, 2020,2020:3467419. doi:10.1155/2020/3467419.
[10]	LIU D, SAIKAM V, SKRADA K A, et al. Inflammatory bowel disease biomarkers[J]. Med Res Rev, 2022, 42(5):1856-1887. doi:10.1002/med.21893.
[11]	GUO X, HUANG C, XU J, et al. Gut microbiota is a potential biomarker in inflammatory bowel disease[J]. Front Nutr, 2021, 8:818902. doi:10.3389/fnut.2021.818902.
[12]	AITTAN E, GRALNEK I M, BERNS M S. The new proactive approach and precision medicine in Crohn's disease[J]. Biomedicines, 2020, 8(7):193. doi:10.3390/biomedicines8070193.
[13]	MURRAY J, KOK K B, AYLING R M. Fecal calprotectin in gastrointestinal disease[J]. Clin Chem, 2023, 69(7):699-710. doi:10.1093/clinchem/hvad051.
[14]	FREEMAN K, WILLIS B H, FRASER H, et al. Faecal calprotectin to detect inflammatory bowel disease:a systematic review and exploratory meta-analysis of test accuracy[J]. BMJ Open, 2019, 9(3):e27428. doi:10.1136/bmjopen-2018-027428.
[15]	HU Z, CANO I, D’AMORE P A. Update on the role of the endothelial glycocalyx in angiogenesis and vascular inflammation[J]. Front Cell Dev Biol, 2021, 9:734276. doi:10.3389/fcell.2021.734276.
[16]	FRANCEKOVIĆ P, GLIEMANN L. Endothelial glycocalyx preservation-impact of nutrition and lifestyle[J]. Nutrients, 2023, 15(11):2573. doi:10.3390/nu15112573.
[17]	YANG J, LEBLANC M E, CANO I, et al. ADAM10 and ADAM17 proteases mediate proinflammatory cytokine-induced and constitutive cleavage of endomucin from the endothelial surface[J]. J Biol Chem, 2020, 295(19):6641-6651. doi:10.1074/jbc.RA119.011192.
[18]	PUCHWEIN-SCHWEPCKE A, GENZEL-BOROVICZENY O, NUSSBAUM C. The endothelial glycocalyx:physiology and pathology in neonates,infants and children[J]. Front Cell Dev Biol, 2021, 9:733557. doi:10.3389/fcell.2021.733557.
[19]	DOGNE S, FLAMION B. Endothelial glycocalyx impairment in disease:focus on hyaluronan shedding[J]. Am J Pathol, 2020, 190(4):768-780. doi:10.1016/j.ajpath.2019.11.016.
[20]	YANY Y, SCHMIDT E P. The endothelial glycocalyx:an important regulator of the pulmonary vascular barrier[J]. Tissue Barriers, 2013, 1(1):e23494. doi:10.4161/tisb.23494.
[21]	AN J, LIU Y, WANG Y, et al. The role of intestinal mucosal barrier in autoimmune disease:a potential target[J]. Front Immunol, 2022, 13:871713. doi:10.3389/fimmu.2022.871713.
[22]	SCHNEIDER H, PELASEYED T, SEVNSSON F, et al. Study of mucin turnover in the small intestine by in vivo labeling[J]. Sci Rep, 2018, 8(1):5760. doi:10.1038/s41598-018-24148-x.
[23]	MARTENS E C, NEUMANN M, DESAI M S. Interactions of commensal and pathogenic microorganisms with the intestinal mucosal barrier[J]. Nat Rev Microbiol, 2018, 16(8):457-470. doi:10.1038/s41579-018-0036-x.
[24]	PARAY B A, ALBESHR M F, JAN A T, et al. Leaky gut and autoimmunity:an intricate balance in individuals health and the diseased state[J]. Int J Mol Sci, 2020, 21(24):9770. doi:10.3390/ijms21249770.
[25]	SEGRIST E, CHERRY S. Using diverse model systems to define intestinal epithelial defenses to enteric viral infections[J]. Cell Host Microbe, 2020, 27(3):329-344. doi:10.1016/j.chom.2020.02.003.
[26]	HANSSON G C. Mucins and the microbiome[J]. Annu Rev Biochem, 2020,89:769-793. doi:10.1146/annurev-biochem-011520-105053.
[27]	LI H, HAO Y, YANG L L, et al. MCTR1 alleviates lipopolysaccharide-induced acute lung injury by protecting lung endothelial glycocalyx[J]. J Cell Physiol, 2020, 235(10):7283-7294. doi:10.1002/jcp.29628.
[28]	HU C, LIAO S, LV L, et al. Intestinal immune imbalance is an alarm in the development of IBD[J]. Mediators Inflamm, 2023,2023:1073984. doi:10.1155/2023/1073984.
[29]	MAGRO D O, KOTZE P G, MARTINEZ C A R, et al. Changes in serum levels of lipopolysaccharides and CD26 in patients with Crohn's disease[J]. Intest Res, 2017, 15(3):352-357. doi:10.5217/ir.2017.15.3.352.
[30]	LAYUNTA E, JAVERFELT S, DOLAN B, et al. IL-22 promotes the formation of a MUC17 glycocalyx barrier in the postnatal small intestine during weaning[J]. Cell Rep, 2021, 34(7):108757. doi:10.1016/j.celrep.2021.108757.
[31]	VILLALBA N, BABY S, YUAN S Y. The endothelial glycocalyx as a double-edged sword in microvascular homeostasis and pathogenesis[J]. Front Cell Dev Biol, 2021, 9:711003. doi:10.3389/fcell.2021.711003.
[32]	NIGHOT M, GANAPATHY A S, SAHA K, et al. Matrix metalloproteinase MMP-12 promotes macrophage transmigration across intestinal epithelial tight junctions and increases severity of experimental colitis[J]. J Crohns Colitis, 2021, 15(10):1751-1765. doi:10.1093/ecco-jcc/jjab064.
[33]	LIN J C, WU J Q, WANG F, et al. QingBai decoction regulates intestinal permeability of dextran sulphate sodium-induced colitis through the modulation of notch and NF-κB signalling[J]. Cell Prolif, 2019, 52(2):e12547. doi:10.1111/cpr.12547.
[34]	WU D, ZHOU J, CREYER M N, et al. Phenolic-enabled nanotechnology:versatile particle engineering for biomedicine[J]. Chem Soc Rev, 2021, 50(7):4432-4483. doi:10.1039/d0cs00908c.
[35]	POLEDNICZEK M, NEUMAYER C, KOPP C W, et al. Micro- and macrovascular effects of inflammation in peripheral artery disease-pathophysiology and translational therapeutic approaches[J]. Biomedicines, 2023, 11(8):2284. doi:10.3390/biomedicines11082284.
[36]	MILUSEV A, DESPONT A, SHAW J, et al. Inflammatory stimuli induce shedding of heparan sulfate from arterial but not venous porcine endothelial cells leading to differential proinflammatory and procoagulant responses[J]. Sci Rep, 2023, 13(1):4483. doi:10.1038/s41598-023-31396-z.
[37]	TAGHAVI S, ABDULAH S, SHAHEEN F, et al. Glycocalyx degradation and the endotheliopathy of viral infection[J]. PLoS One, 2022, 17(10):e0276232. doi:10.1371/journal.pone.0276232.
[38]	DERKACZ A, OLCZYK P, OLCZYK K, et al. The role of extracellular matrix components in inflammatory bowel diseases[J]. J Clin Med, 2021, 10(5):1122. doi:10.3390/jcm10051122.
[39]	DERKACZ A, OLCZYK P, JURA-POLTORAK A, et al. The diagnostic usefulness of circulating profile of extracellular matrix components:sulfated glycosaminoglycans(sGAG),hyaluronan(HA) and extracellular part of Syndecan-1(sCD138) in patients with Crohn's disease and ulcerative colitis[J]. J Clin Med, 2021, 10(5):1122. doi:10.3390/jcm10051122.
[40]	FLOER M, CLAUSEN M, MEISTER T, et al. Soluble syndecan-1 as marker of intestinal inflammation:a preliminary study and evaluation of a new panel of biomarkers for non-invasive prediction of active ulcerative colitis[J]. Adv Clin Exp Med, 2021, 30(7):655-660. doi:10.17219/acem/139040.